# **ENVIRONMENT**& HEALTH


pubs.acs.org/EnvHealth

# Association of Di(2-ethylhexyl) Phthalate Exposure with Reproductive Hormones in the General Population and the Susceptible Population: A Systematic Review and Meta-Analysis

Xuanxuan Li,<sup>#</sup> Changchun Xiao,<sup>#</sup> Jintao Liu, Ning Wei, Jian Song, Jiajun Yuan, Li Liu, Rong Song, Weizhuo Yi, Rubing Pan, Jian Cheng, Shusi Wang,\* and Hong Su\*



mental endocrine disruptor, has hormone-like activity and endocrine-disrupting effects. However, the types of reproductive hormones associated with DEHP vary across the studies. Thus, we conducted a systematic review and meta-analysis to pool existing epidemiological evidence. We searched three databases up to January 31, 2024, for eligible original studies to ultimately include 37 studies from eight countries with a total of 28 911 participants. DEHP exposure was evaluated with urinary metabolites. Since the main types, production sites, blood concentrations, and functions of reproductive hormones differ between men and women, we reported the combined effect values by gender. Subgroup analyses were conducted by age, subfertility status, and the national



sociodemographic index (SDI) level. Furthermore, the effect of maternal exposure during pregnancy on children's reproductive hormone levels was analyzed separately. Overall, in general, in men, DEHP was positively correlated with sex hormone bindingglobulin (SHBG) and adversely correlated with total testosterone (TT), free androgen index (FAI), and follicle-stimulating hormone (FSH). Results indicated that among men of reproductive age, DEHP exposure was associated with more significant hormonal suppression in infertile men compared with fertile men. Notably, age subgroup analysis among women revealed that postmenopausal women were more vulnerable to DEHP, which was related to lower TT and estradiol ( $E_2$ ). However, this study did not observe a significant association between prenatal DEHP metabolites and reproductive hormone levels in children. Our research identifies the most susceptible hormones (androgen suppression) after DEHP exposure and suggests that infertile men and postmenopausal women are in great need of more attention as sensitive populations.

KEYWORDS: Di(2-ethylhexyl) phthalate, DEHP, Reproductive hormones, Endocrine disruptors, Meta-analysis

# 1. INTRODUCTION

Phthalates are a group of semivolatile organic compounds (SVOC) commonly used as plasticizers and softeners in a wide range of household and industrial products, including toys, food packaging, medical devices, building materials, and cosmetics.<sup>1</sup> Among them, di(2-ethylhexyl) phthalate (DEHP) is the most extensively used phthalate derivative in polyvinyl chloride products and the most studied to data.<sup>2,3</sup> As additives not covalently bound to materials, DEHP is easily released through volatilization during manufacture, storage, use, and disposal and easily enters the atmosphere, food, or body fluids.<sup>4</sup> Humans are generally exposed to DEHP through inhalation, ingestion, drinking, and skin contact.<sup>5,6</sup> Studies have identified DEHP as the most hazardous chemical additive to health in plastics on the basis of human health hazard scores.<sup>7</sup> Thus, it is urgent to determine the potential health effects of DEHP.

DEHP is commonly recognized as an endocrine-disrupting chemical because it disrupts the human endocrine system by attaching to molecular targets and interfering with hormonal balance.<sup>8–10</sup> Adverse effects of DEHP exposure on reproductive hormones have been widely reported with plausible mechanisms described. It has been suggested that DEHP exposure blocks the binding of endogenous hormones to receptors mainly through receptor-mediated responses, thereby leading to endogenous hormone antagonistic effects.<sup>11</sup> In addition, DEHP disrupts the synthesis, metabolism, and

Received: February 28, 2024 Revised: June 4, 2024 Accepted: June 7, 2024 Published: July 5, 2024





ACS Publications © 2024 The Authors. Co-published by Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, and American Chemical Society

transport of endogenous hormones and their receptors.<sup>12</sup> Studies on rodents have shown that DEHP exhibits antiandrogenic activity resulting in reduced testosterone levels and abnormal reproductive tracts. Epidemiologic studies on populations have shown that DEHP exposure is associated with altered steroid hormone levels in men,<sup>13,14</sup> women,<sup>15,16</sup> and children.<sup>17,18</sup> However, the types of reproductive hormones associated with DEHP and the direction of the association varied across studies.<sup>19–23</sup>

The balance of reproductive hormones in the body is regulated by the hypothalamic-anterior pituitary-gonad (HPG) axis.<sup>24</sup> In brief, the hypothalamus secretes gonadotropin-releasing hormone (GnRH), which subsequently stimulates the synthesis and release of gonadotropins from the anterior pituitary.<sup>18</sup> The gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) stimulate the gonads to synthesize and release reproductive hormones (i.e., steroids). Then, the male testes produce testosterone (T), and the female ovaries produce estradiol  $(E_2)$  and progesterone (PROG). Sex hormone binding-globulin (SHBG) is a glycoprotein synthesized by the liver and testes that transplants sex hormones, such as T and E<sub>2</sub>, into target cells.<sup>25</sup> Existing studies of reproductive hormones mainly involve three gonadotropins [LH, FSH, and prolactin (PROL)], one estrogen  $(E_2)$ , one progestin (PROG), one androgen (T), and one carrier (SHBG). There are sex differences in the main types, sites of production, blood concentrations, and functions.<sup>26,27</sup> Moreover, the balance of reproductive hormones varies according to different physiological stages, such as childhood, adulthood, pregnancy, and menopause.<sup>2</sup> Furthermore, disruption of sex steroid hormones is associated with tumors,<sup>29</sup> obesity,<sup>30</sup> metabolic syndrome,<sup>15</sup> and cardiovascular disease.<sup>31</sup> Therefore, exploring the types of hormones affected by DEHP and identifying susceptible populations are crucial to elucidate the mechanism of DEHP on health.

After exposure to DEHP, it is initially metabolized to mono-(2-ethylhexyl) phthalate (MEHP) and then further metabolized to several secondary metabolites, including mono-(2ethyl-5-oxohexyl) phthalate (MEOHP), mono-(2-ethyl-5hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP), and mono-[2-(carboxymethyl)hexyl] phthalate (MCMHP).<sup>32</sup> It is generally believed that MEHP is mainly responsible for the biological activity exerted by DEHP exposure.<sup>2,33</sup> Urine and blood are the most commonly used substrates for DEHP biomonitoring, and the concentration of metabolites found in urine is higher than that in blood because of its rapid metabolism and elimination, which may reflect prolonged exposure.<sup>34</sup> Urine is considered to be the most reliable substrate for the assessment of DEHP exposure.<sup>10</sup> It has been found that the higher detection rates of MEOHP and MEHHP than MEHP in urine suggest that these two oxidative metabolites make low-level exposures more detectable.<sup>35</sup> Thus, the three urinary metabolites, MEHP, MEOHP, and MEHHP, have been widely used to explore the relationship between DEHP exposure and adverse health outcomes. The focus of this study was to use the levels of three metabolites in urine to reflect the body's exposure to DEHP.

On the basis of the heterogeneity of previous studies, a systematic review and meta-analysis were performed to summarize the available results between DEHP exposure and reproductive hormone levels with an aim to (1) identify which reproductive hormone changes are associated with DEHP metabolites concentration, (2) assess the magnitude and

direction of the association, and (3) explore susceptible subpopulations.

# 2. METHODS

# 2.1. Study Protocol

We conducted this meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) rules.<sup>36</sup> The study protocol has been registered with PROSPERO (ID CRD42023429873).

# 2.2. Search Strategy

We searched for original studies in the Web of Science, PubMed, and The Cochrane Library until January 31, 2024. The keywords covered "DEHP" and "reproductive hormone," and the final search strategies are shown in Table S1. Additionally, the reference lists of the included studies and related reviews were screened for inclusion of all relevant articles. Two authors (X.X.L. and J.T.L.) performed initial screening by title and abstract, respectively, and then obtained the full text for further screening. Data extraction and quality assessment were also performed by the same two authors. Disagreements in the process were arbitrated by a third author (N.W.).

# 2.3. Inclusion and Exclusion Criteria

Studies meeting the following criteria were included: (1) original research in English; (2) observational study, including case control, cross-sectional, and prospective and retrospective studies; (3) studies conducted in populations; (4) DEHP exposure evaluated by at least one of the urinary metabolites, including MEHP, MEHHP, and MEOHP; (5) study outcomes were serum reproductive hormone concentrations, which included at least one of LH, FSH, PROL,  $E_2$ , PROG, total testosterone (TT), free testosterone (FT), SHBG, free androgen index (FAI), dehydroepiandrosterone (DHEA-S), and human choionic gonadotophin (HCG); and (6) effect sizes were reported as regression coefficient ( $\beta$ ), percentage change (PC), mean difference (MD), correlation coefficient (r), and 95% confidence interval (CI).

There were exclusion criteria: (1) if the papers were abstracts, reviews, letters, or conference papers, etc.; (2) if the papers were nonoriginal research or toxicological studies; (3) if DEHP metabolite levels were not measured through urine, and reproductive hormone levels were not measured through the serum; and (4) if effect values were not available or could not be translated.

# 2.4. Data Extraction and Management

The following information was extracted from each included study: author's name, publication year, study location, study period, population characteristics (age, gender, subfertility status), sample size, study design, exposure, outcomes, effect sizes, and 95% CI.

If studies reported both continuous and categorical outcomes of the DEHP metabolite concentration, we preferred continuous data. Since the distributions of DEHP and reproductive hormones in humans do not satisfy an approximately normal distribution in some studies, different log-transformed methods were used before estimating effect values. For a relatively uniform meta-analysis, we homogenized the results of the different studies.<sup>37</sup> Effect values were converted to the percentage change in reproductive hormone per 1  $\mu$ g/L increase in the DEHP concentration. When  $\beta$  and *P* values were reported in the original data, 95% CI values were




Figure 1. Flowchart of the literature search and selection for meta-analysis.

recalculated using the previous equation.<sup>38</sup> Studies where DEHP metabolites concentration were categorically defined were combined for effect values only in sensitivity analyses.<sup>16,18,21</sup>

#### 2.5. Quality Assessment

A formal quality assessment of screened studies was performed using a systematic and standardized approach referencing the quality assessment methods used in previous meta-analyses related to phthalate.<sup>39</sup> In brief, quality scores were based on 15 items, including study design, study population, measurement of phthalate concentrations, covariate adjustment, interference from other chemicals, exposure-response analysis, and sensitivity analysis. One point was added for methodological strengths, and one point was subtracted for each apparent weakness. All discrepancies in uncertainty were discussed and resolved by consensus among the three evaluating authors. Studies with scores higher than -2 were included in the quantitative analysis of the associations between phthalates and their metabolite levels in humans and reproductive hormones.

# 2.6. Data Analysis

The  $I^2$  statistics and Cochran's Q test were used to describe heterogeneity.<sup>40</sup> Pooled estimates were calculated on the basis of the random effects model when  $I^2$  values > 50%; if not, the fixed effects model was used.<sup>41</sup> Q-tests with p < 0.05 were considered statistically significant for heterogeneity.<sup>42</sup> Publication bias was assessed by funnel plot analysis and Egger's regression test.

We performed subgroup analyses by age, subfertility status, and national sociodemographic index (SDI) level. Studies were separated into three age subgroups on the basis of the characteristics of reproductive hormone distribution at different ages: <20 years, 20-45 years, and >45 years. Additionally, the link between DEHP metabolite concentration and reproductive outcomes has been investigated primarily in

infertile males. Because of a more fragile hormonal homeostasis system in infertile men, the association may differ from that in the general population. Therefore, a subgroup analysis on the basis of the reproductive age population was performed. Moreover, SDI is a composite indicator calculated by per capita income, total fertility rate, and average level of education, which represents a country's level of development. Subgroup analyses were performed on the basis of the SDI level of countries to take into account the potential heterogeneity of multiple studies.

Fetuses are more vulnerable to toxic chemicals and exposed to DEHP from maternal to the amniotic fluid. Exposure to hormone mimics during fetal development may be harmful to health after birth, during childhood, or even in adulthood.<sup>43</sup> However, evidence on the impact of fetal exposure to DEHP on reproductive hormones in prepubertal children remains inconsistent. Therefore, the effect of maternal exposure during pregnancy on children's reproductive hormone levels was analyzed separately.

The robustness of the results was verified by a sensitivity analysis. First, the leave-one-out meta-analysis was used to verify whether the combined effect size changed significantly after each study. Besides, the bias caused by using standardized regression coefficients in the meta-analysis to estimate missing correlations was even larger.<sup>44</sup> The quality of the articles reporting a correlation coefficient is relatively low because of other exposures and covariates not being controlled. Therefore, a separate meta-analysis of articles reporting correlation coefficients was conducted for the sensitivity analysis. Among women, hormone levels may be more variable in pregnant women compared with nonpregnant women. So, sensitivity analyses for studies that excluded pregnant women were conducted.

All statistical analyses were performed with Stata 13.0 and R v3.1.0.

# 3. RESULTS

### 3.1. Characteristics of Included Studies

As shown in Figure 1, 4412 studies were initially searched. After reviewing the abstracts and removing duplications, 116 articles underwent a full-text review, and finally, 44 articles met the criteria. After quality assessment, a total of 37 studies were considered high quality, while the other 7 were of low quality. The details of the scores for each article are shown in Table S2. Ultimately, this systematic review comprised 37 studies, of which 28 were included in the meta-analysis.<sup>13–15,17,19,20,22,23,45–64</sup> Five articles<sup>16,18,21,65,66</sup> included exposure as a categorical variable, two studies<sup>67,68</sup> had data that could not be transformed, and two studies<sup>69,70</sup> had a unique hormone that was not included in the meta-analysis.

Table 1 presents the characteristics of studies included in the systematic review. There were 28 cross-sectional studies, three mother—infant cohort studies, three case control studies, and two panel studies. These studies were conducted in eight countries. There were 27 articles for males and 22 articles for females in this systematic review. The number of meta-analyses was 20 for males and 12 for females, with 4 articles containing both genders. Study subjects were composed of newborns, children, adolescents, adults, infertile populations, pregnant women, and workers, involving a total of 28 911 participants.

Liquid chromatography-tandem mass spectrometry (LC-MS), high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS), and ultrahigh-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) were used to determine the concentration of DEHP metabolites. These methods are currently recognized with reliable results, low limits of detection, and good reproducibility.<sup>71-73</sup> Reproductive hormone levels in serum were detected by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), chemiluminescence immunoassay (CLIA), electrochemiluminescence immunoassay (ECLIA), and LC-MS. LC-MS was the most sensitive method, but CLIA and ECLIA were the most commonly used methods.74,75 However, there is no uniform standard for reproductive hormone testing. The hormone levels obtained in different laboratories by different methods may differ. Therefore, the effect values in this meta-analysis were converted to relative changes in reproductive hormones to avoid the effects of assay methods.

Among the five metabolites of DEHP, the most frequently measured, MEHP, MEHHP, and MEOHP, were metaanalyzed in this study. The number of studies on various DEHP included in this review is as follows: MEHP (N = 38), MEHHP (N = 30), and MEOHP (N = 29). TT, E<sub>2</sub>, FSH, and SHBG were the hormones with the highest numbers of studies at 30, 27, 21, and 18, respectively. Meta-analysis was conducted when the number of articles was more or equal to three.

# 3.2. Association between DEHP and Reproductive Hormones in Males

A pooled analysis of 20 studies estimated the association between urinary DEHP metabolite concentrations and male reproductive hormones, as shown in Figure 2. Overall, in males, DEHP levels were positively correlated with SHBG and negatively correlated with TT, FAI, and FSH. For each 1  $\mu$ g/L increase in MEHHP, MEHP, and MEOHP, FAI levels changed by -0.07799% (95% CI: -0.12216%, -0.03382%), -0.22769% (95% CI: -0.33557%, -0.11981%), and

-0.14837% (95% CI: -0.22017%, -0.07656%), respectively. There were negative correlations between MEHP and TT [-0.03649% (95% CI: -0.06640%, -0.00658%)] and MEOHP and FSH [-0.00733% (95% CI: -0.01410%, -0.00056%)]. The analysis between MEOHP and SHBG showed a positive correlation with pooled coefficients of 0.00605% (95% CI: 0.00229%, 0.00981%). There was no evidence of a relationship between DEHP and LH, inhibin B, FT, E<sub>2</sub>, DHEA-S, or PROG.

# 3.3. Association between DEHP and Reproductive Hormones in Females

As shown in Figure 3, the pooled analysis did not reveal a significant correlation between DEHP metabolite concentration and the levels of TT, SHBG,  $E_2$ , PROG, and FT. For the association of DEHP metabolites with PROL, three articles presented completely disparate findings with a cumulative effect value for MEHP of 0.13881% (95% CI: -0.17846%, 0.45607%). Significant results were reported among articles insufficient for meta-analysis. Adibi et al. found significant associations between MEHP with disrupting placental HCG in pregnant women, thus leading to shortened anogenital distance in boys.<sup>69</sup> Higher exposure to several phthalates, including all metabolites of DEHP, was associated with lower HCG<sup>77</sup> and higher FSH.<sup>17,64</sup>

#### 3.4. Subgroup Analyses

Subgroup analyses were conducted by age, subfertility status, and the national SDI level.

In the age subgroup analysis of women, all study subjects in the high-age groups were postmenopausal women. Above all, postmenopausal women were more sensitive to DEHP than younger women (Figure 4). The results showed that in women over 45 years old, with each 1  $\mu$ g/L increase in MEHHP, MEHP, and MEOHP, TT levels changed by -0.04539% (95% CI: -0.07296%, -0.01782%), -0.04828% (95% CI: -0.07605%, -0.01486%), and -0.04828% (95% CI: -0.07605%, -0.02050%), respectively. Increases in MEOHP were linked to decreases in E<sub>2</sub> [-0.05349% (95% CI: -0.08825%, -0.01873)]. In contrast, the age subgroup of males did not show any statistically diverse outcomes (Table S4).

In infertile men, an increased DEHP metabolite concentration was associated with reduced FT, FSH, and FAI concentrations (Figure 5). The meta-analysis found that each 1  $\mu$ g/L MEHHP, MEHP, and MEOHP increase was associated with -0.02783% (95% CI: -0.05509%, -0.00056%), -0.16234% (95% CI: -0.32093%, -0.00375%), and -0.04718% (95% CI: -0.08824%, -0.00612%) change in FAI, respectively. Increases in MEHHP and MEOHP were linked to decreases in FT [-0.00497% (95% CI: -0.00980%, -0.00014)] and FSH [-0.00750% (95% CI: -0.01489%, -0.00011], and increases in MEOHP were linked to decreases in FSH [-0.00801% (95% CI: -0.01551%, -0.00050)]. Al-Saleh et al. observed that DEHP metabolites were associated with low PROL levels.<sup>47</sup> Chang et al. reported no associations between DEHP metabolites and inhibin B in infertile men.<sup>14</sup> However, the meta-analysis in fertile men of reproductive age did not find a significant association between DEHP and alterations in TT, SHBG, LH, FSH, or E<sub>2</sub> (Table S5). The association of DEHP with other hormones was not meta-analyzed because of the insufficient number of articles. Only two articles reported a significant negative correlation between MEOHP and FAI.<sup>55,58</sup> There was only one study in a

	••••••		Ticulti						passia	colorg/c	Inviteditii					
	significance re- sult	MEHP-TT (–), E, (+)	MEHHP-TT (-), SHBG (+)	MEOHP-TT (-), SHBG (+)	MEHHP-SHBG (-)	none	MEHP-TT, FT, BT, FAI $(-)$ MEHHP- $E_2$ (-)	MEOHP- E <sub>2</sub> , FT, BT, FAI (–)	none	MEHP-TT (-)	MEHHP-FSH (-) (-) (-)	MEHP-inhibin B (-)	MEHP- $E_2$ , TT (-), TT/ $E_2$ (+) MEOHP-FAI (-)	MEHP-TT, $E_2$ , FAI, FT $(-)$ , TT/ $E_2$ $(+)$	MEHHP-FT, FAI (-), SHBG (+) MEOHP-FT, FAI (-), SUBC (-),	MEHP-TT (-)
	effect value type	β			β	β	PC		β	β	OR	β	β	β, r		β
	study de- sign	cross-sec- tional	study		cross-sec- tional study	cross-sec- tional study	cross-sec- tional study		case-con- trol study	case-con- trol study	case-con- trol study	mother– infant cohort	cross-sec- tional study	cross-sec- tional study		cross-sec- tional study
	statistical analysis	linear regression model			generalized linear model with a Poisson family distribution and log link	multivariate linear regres- sion	survey-weighted multivari- able linear regression models		multiple linear regression models	linear regression models	binary logistic regression models	generalized estimating equations (GEE) models	multivariable linear regres- sion	Mann–Whitney U test and Pearson correlation coef- ficients		linear regression model
	reproductive hor- mone type	$E_2$ , TT, SHBG			TT, SHBG	TT, $E_{2}$ SHBG	TT, E <sub>2</sub> , FT, FAI, SHBG		TT	FSH, LH, TT, E <sub>2</sub> , SHBG, inhibin B, FT, FAI	E <sub>2</sub> , FSH	TT, FSH, LH, inhibin B	FSH, LH, inhibin B, TT, SHBG, FAI, E <sub>2</sub> , PROL	FSH, LH, TT, E <sub>2</sub> SHBG, FAI, FT		TT, E <sub>2</sub> , FSH
alysis	DEHP ex- posure type	MEHP, MEHHP,	MEOHP		MEHP, MEHHP, MEOHP	MEHHP, MEOHP	МЕНР, МЕННР, МЕОНР		MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP	МЕНР, МЕННР, МЕОНР	MEHP, MEHHP, MEOHP		MEHP
Meta-An	sex: N	M: 1056	F: 1108		F: 7561	F: 279	F: S4S		M: 167	M: 176	F: 419	mother– infant: 83	M: 425	M: 850		M: 269
Table 1. Principal Characteristics of Studies Included in the Systemic Keview and Meta-Analysis.	population	adults			female participants aged 15 years or older	gids aged 12–19 years	women over the age of 20		57 boys with CDGP (cases) and 110 controls	infertile men (25–45 years old) fertile men (21–40 years old)	173 women determined to meet the diagnosis of POF and 246 healthy women <40 years	mother-infant	men who were partners in subfertile couples seeking treatment	Study for Future Families (SFF): men who were partners of pregnant women;	Massachusetts General Hospital (MGH): men with male factor infertility, as well as men who are partners of women with female factor infertility	men who were attending an infertility clinic
cs of Str	location	United States			United States	United States	United States		China	China	China	Mexico	United States	United States		Poland
ncipal Characteristi	data period	2015-2016			2013-2016	2013-2016	2013-2016		<sup>62</sup> 2013–2014	2010-2012	2015-2017	÷	January 2000 to May 2004	1999–2005		2007
Table I. Pri	study	Zhu et al. (2022) <sup>63</sup>			Dubey et al. (2022) <sup>15</sup>	Bigambo et al. (2022) <sup>49</sup>	Long et al. (2021) <sup>67</sup>		Xie et al. (2015) <sup>62</sup>	Wei-Hsiang Chang et al . (2015) <sup>14</sup>	Cao et al. (2020) <sup>16</sup>	Bustamante-Mon- tes et al. (2021) <sup>50</sup>	Meeker et al. (2009) <sup>58</sup>	Mendiola et al. (2012) <sup>13</sup>		Jurewicz et al. (2013) <sup>57</sup>

754

Review

ivi	ronme	nt &	Hea	lth						pubs.a	cs.or	g/Envl	Health								Review
	significance re- sult	MEHP-FT $(-)$ , SHBG $(+)$	(+)	MEOHP-SHBG (+)	MEHP- E <sub>2</sub> , INSL3 (–)	none	MEHP-TT, E <sub>2</sub> , FT (–)	MEHP-TT, TT/ LH (–), E <sub>2</sub> (+)	MEHHP-TT, TT/LH $(-)$ , E <sub>2</sub> , SHBG $(+)$	MEOHP-TT $(-), E_2$ SHBG (+)	MEHP-PROG (-)	MEHHP-TT (-)	MEOHP- $E_2$ , TT, PROG (-)	none	MEHHP-FSH (-)	MEOHP-FSH PROL (–)	MEHP- $E_2$ (+)	MEHHP- $E_2$ (+) MEOHP- $E_2$ (+)	MEHP-TT (+)	none	MEHP-inhibin B (-)
	effect value type	PC			PC	β	$\beta$ , PC	PC			PC			PC	β		β		β	β	β
	study de- sign	cross-sec- tional	study		cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study			cross-sec- tional	study		cross-sec- tional study	cross-sec- tional	study	cross-sec- tional	study	panel study	cross-sec- tional study	cross-sec- tional study
	statistical analysis	linear regression models			multivariate linear regres- sion models	regression models	multivariate linear regres- sion models	multiple linear regression			linear regression or mixed model			unadjusted linear regression models	Pearson correlation coeffi- cients		multivariate linear regres- sions	20010	Wilcoxon signed-rank test	multiple linear regression analysis	multivariable linear regres- sion
	reproductive hor- mone type	DHEA-S, $E_2$ in- hibin B, SHBG,	TT, FT		TT, LH, FSH, E <sub>2</sub> SHBG, FAI, FT	TT, FT, LH, FSH, E <sub>2</sub> , SHBG	TT, FT, LH, FSH, E <sub>2</sub> , SHBG, FAI	TT, E <sub>2</sub> , LH, FSH, SHBG			E <sub>2</sub> , FSH, LH, PROL, PROG,	ΤΤ		LH, TT, TSH	FSH, LH, E <sub>2</sub> , PROL, TT		LH, FSH, SHBG, inhihin B F.	TT, FT	TT, FT, FSH, LH, E <sub>2</sub> ,	FSH, TT, LH	AMH, inhibin B
	DEHP ex- posure type	МЕНР, МЕННР,	MEOHP		MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP			MEHP, MEHHP,	MEOHP		MEHP, MEHHP, MEOHP	МЕНР, МЕННР,	MEOHP	МЕНР, МЕННР	MEOHP	MEHP	MEHP, MEHHP	MEHP, MEHHP, MEOHP
	sex: N	M: 118			M: 1066	M: 314	M: 483	M: 290			M: 796			M: 117	M: 599		M: 207		M: 97	M: 88	F: 415
	population	boys			male partners of infertile couples	young men	male partners of couples attending an infertility clinic	male partners of subfertile and fertile couples			male students			men aged between 18 and 41 years	men attending an in vitro fertilization clinic		elderly men with urologist-diagnosed benign prostatic hymerrilasia (RDH) and myostatic enlargement	بالمحدثة معالم المعالم فالم فالمعالم والمعاجبا والمعاجبا والمعاد	male workers from factories in the plastics industry	male partners of couples and diagnosed as infertile	women seeking infertility treatment
	location	Mexico			China	Sweden	China	China			China			Canada	Saudi Arabia		China		French	China	China
	data period	1994–2004 recruit	2010 follow-up		2012-2014		from March to June 2013	November 2010 to March 2014			2013			2009-2012	2015-2017		2015-2017		2015-2018	2015	<sup>5</sup> 2016
1 anic 1. Coll	study	Ferguson et al. (2014) <sup>56</sup>	~		Pan et al. (2015) <sup>19</sup>	Axelsson et al. (2015) <sup>48</sup>	Wang et al. (2016) <sup>20</sup>	Chang et al. (2017) <sup>52</sup>			Chen et al. (2017) <sup>21</sup>			Albert et al. (2018) <sup>46</sup>	Al-Saleh et al. (2019) <sup>47</sup>		Chang et al.		Henrotin et al. (2020) <sup>68</sup>	Wang et al. (2020) <sup>59</sup>	Du et al. (2018) <sup>55</sup>

755

Table 1. continued

https://doi.org/10.1021/envhealth.4c00046 Environ. Health 2024, 2, 750–765

VII	ronme	πœ	пеан	11				pu	ps.acs.o	org/EnvHealth				Review
	significance re- sult	MEOHP-inhibin B (–)	none	MEHP- $E_2$ (-) MEOHP- $E_2$ (-)	none	MEHP-PROG (+)	MEHP-TT (-)	MEHP-FSH (-) MEHHP-FSH (-) MEOHP-FSH (-)	none	MEHP-TT, FSH (-) MEHHP-TT, LH (+) MEOHP-TT, FSH, LH, PROG (-)	MEHP- $E_2$ (-) MEHHP- $E_2$ , TT/ $E_2$ (-) MEOHP- $E_2$ , TT/ $E_2$ (-)	MEHP-HCG (-)	MEHP-AMH (-) MEHHP-AMH (-) MEOHP-AMH (-)	MEHP- HCG (-)
	effect value type		PC	DD	PC	β	β	r, OR	β	RR	β	β	PC	β
	study de- sign		mother– infant cohort	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	cross-sec- tional study	mother – infant cohort	panel study	cross-sec- tional study
	statistical analysis		linear regression	multiple linear regression	linear mixed model	simple linear and binary logistic regression analy- ses	generalized additive models	Spearman's correlation	generalized estimating equation (GEE) linear regression analysis	multivariate binary logistic regression models	multiple linear regression	multiple linear regression	multivariable linear mixed- effect models	multivariable linear regres- sion model
	reproductive hor- mone type		E <sub>2</sub> , TT, SHBG, DHEA-S, inhibin B	FT, TT, E <sub>2</sub>	E <sub>2</sub> , SHBG, PROG, TT	E <sub>2</sub> , FSH, FT, PROG, TT	$\mathrm{TT}$	LH, FSH, E <sub>2</sub> , TT, FT, SHBG	E <sub>2</sub> , TT, FT, PROG	FSH, PROL, LH, E <sub>2</sub> , PROG, TT	TT, E <sub>2</sub> , SHBG, FAI, FT	HCG	AMH, FSH, SHBG	НСС
	DEHP ex- posure type		MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP	MEHP	MEHP, MEHHP, MEOHP	MEHP, MEHHP, MEOHP
	sex: N		F: 128	mother– infant: 591	F: 677	F: 69 M: 61	M: 313 F: 473	: F: 90 M: 132	F: 97 M: 94	F: 58 M: 48	M: 319 F: 294	F: 541	F: 3302	F: 2039
	population		pregnant women and their offspring	The Infant Development and the Environment Study	pregnancy 16 to 20 weeks and 24 to 28 weeks station	children 8 years old and their mothers	adults (aged 20–30)	children aged <12 years old in issue of the illegal use of phthalates as clouding agents in food products	mother-infant	residents aged 11–88 years	participants aged 12–19 years old	pregnant women	female aged 42 to 52 years	pregnant women
	location		Mexico	United States	United States	China	China	China	China	China	United States	United States	United States	Sweden
	data period		1997–2004, recruit 2010 follow-up	: 2010-2012	2012-2017	2001-2009	2006-2008	2011	2000–2001, recruit 2003, 2006, 2009, 2012 follow-up	2014-2015	2013-2016	2010-2012	1996–2003	2007-2010
	study		Watkins et al. (2014) <sup>60</sup>	Sathyanarayana et al. (2017) <sup>23</sup>	Cathey et al. (2019) <sup>51</sup>	Su et al. (2014) <sup>17</sup>	Chen et al. (2017) <sup>53</sup>	Wen et al. (2017) <sup>18</sup>	Wen et al. (2017) <sup>61</sup>	Zhang et al. (2019) <sup>65</sup>	Aimuzi et al. (2022) <sup>45</sup>	Adibi et al. (2015) <sup>69</sup>	Ding et al. (2023) <sup>54</sup>	Derakhshan et al. (2023) <sup>77</sup>

# **Environment & Health**

Review

756

Table 1. continued

Envi	ronme	nt & Hea	lth		
	significance re- sult	MEHHP- HCG (-) MEOHP- HCG (-)	none	MEHP- FSH (+) MEHHP- FSH (+) MEOHP- FSH (+)	, free and rogen e; $\beta$ , regression
	effect value type		β	PC	ne; FAL M, mal
	study de- sign		panel study	cross-sec- tional study	lating hormor in; F, female;
	statistical analysis		generalized linear models	generalized linear models	rone; FSH, follicle-stimu hormone; PROL, prolact
	reproductive hor- mone type		$TT$ , $E_2$	E., FSH, LH, PROG	oavailable testoste H, anti-Müllerian
	DEHP ex- posure type		MEHP, MEHHP, MEOHP	МЕНР, МЕННР, МЕОНР	erone; BT, bi lotophin; AM
	sex: N		F: 399 M: 430	F: 1228	ig hormone; FT, free testosterone; BT, bioavailable testosterone; FSH, follicle-stimulating hormone; FAI, free androgen HCG, human choionic gonadotophin; AMH, anti-Müllerian hormone; PROL, prolactin; F, female; M, male; $\beta$ , regression
	population		child	women attempting pregnancy	$^{a}$ TT, total testosterone; SHBG, sex hormone binding-globulin; LH, luteinizing hormone; FT, free testosterone; BT, bioavailable testosterone; FSH, follicle-stimulating hormone; FAI, free androgen index; E <sub>2</sub> , estradiol; DHEA-S, dehydroepiandrosterone; PROG, progesterone; HCG, human choionic gonadotophin; AMH, anti-Müllerian hormone; PROL, prolactin; F, female; M, male; $\beta$ , regression
	location		China	United States	ex hormone l ydroepiandro
tinued	data period		6 2017-2020	2007–2011	osterone; SHBG, s diol; DHEA-S, deh
Table 1. continued	study		Liu et al. (2023) <sup>66</sup> 2017–2020	Nobles et al. (2023) <sup>64</sup>	<sup><i>a</i></sup> TT, total test index; $E_2$ , estra

coefficient; PC, percentage change; PD, percent difference; r, correlation coefficient; OR, odds ratio; RR, relative risk; (+), positive correlation; (-), negative correlation; N, sample size.

female infertile population that reported the association of DEHP metabolites with inhibin B. Therefore, a subgroup analysis by fertility was not available among women.

Additionally, analysis by country subgroups indicated that the association between MEHHP, MEOHP, and FSH was significantly negative in high-middle SDI countries (Tables S6 and S7). Furthermore, a total of five studies investigated the association between prenatal DEHP metabolite concentration and reproductive hormone levels in children, and no significant relationship was observed in this meta-analysis (Table S8).

#### 3.5. Sensitivity Analysis and Publication Bias

The leave-one-out meta-analysis was used to evaluate the stability of the pooled estimates. The results are presented in Figures S1–S15, which suggest that the pooled effect estimates between all DEHP metabolites with reproductive hormones (TT, SHBG, LH, inhibin B, FSH, FAI) remained stable, except for PROL, FT, and E<sub>2</sub> in males and PROG in female. In addition, the results of the combined articles reporting correlation coefficients also showed that MEHP was negatively correlated with FT and FAI, and all DEHP metabolites were positively correlated with FSH in males (Figures S16 and S17). Moreover, meta-analyses conducted in studies excluding pregnant women did not reverse the pooled effects in females (Figures S20).

Although Egger's tests revealed publication bias in the association of DEHP metabolite concentrations with TT, PROL, FT, and FSH (P < 0.05) (Table S9), further trim-andfill analyses indicated no reversal of the pooled effect values before and after adjustment; thus, the results are robust (Table S10).

# 4. DISCUSSION

A total of 37 articles from eight countries were examined in this systematic review and meta-analysis to assess the relationship between urinary levels of DEHP metabolites and serum reproductive hormones. There was significant gender specificity in the association of DEHP with reproductive hormones. A pooled analysis of 20 studies conducted in men showed that DEHP was positively correlated with SHBG and negatively correlated with TT, FAI, and FSH. However, DEHP was not significantly associated with reproductive hormones in overall women. It is noteworthy, however, that an age subgroup analysis of women showed that postmenopausal women were more sensitive to DEHP, which was associated with lower TT and E<sub>2</sub>. Furthermore, no significant association between DEHP and reproductive hormone alterations was found in men of childbearing age. However, in infertile men, increased concentrations of DEHP metabolites were associated with reduced FT, FSH, and FAI levels.

The association of TT with DEHP is the most studied among all of the reproductive hormones. TT is crucial for the male reproductive system, as well as male fertility. Low TT levels can cause adverse conditions (e.g., prostatic enlargement, decreased fertility, decreased bone mineral density,<sup>78</sup> osteoporosis, and depression<sup>79</sup>). Numerous studies revealed that both high- and low-dose exposure to DEHP decreased circulating testosterone concentrations in adult animals.<sup>80,81</sup> Although the mechanism underlying how DEHP exposure affects TT has not been fully demonstrated, the available experimental studies provide several possible avenues of explanation. First, studies in rats have shown that DEHP-induced reductions in testosterone are achieved by repressing some genes involved in cholesterol

DEHP	No. of articles		PC (95%CI)	Model	<b>/</b> ²(%)	p-value
TT						
MEHHP	17	<b>⊢</b> ∎-1	-0.00450 (-0.02267 to 0.01367)	Random	56.7	0.002
MEHP	20	*	-0.03649 (-0.06640 to -0.00658)	Random	53.8	0.002
MEOHP	16	⊢ <del>_</del>	-0.01627 (-0.04186 to 0.00932)	Random	52.5	0.007
SHBG						
MEHHP	11	• *	0.00266 (0.00064 to 0.00468)	Fixed	31.7	0.146
MEHP	11		0.00441 (-0.00415 to 0.01297)	Fixed	27.5	0.183
MEOHP	11	• *	0.00605 (0.00229 to 0.00981)	Fixed	47.6	0.039
LH						
MEHHP	10	-	-0.00269 (-0.00722 to 0.00183)	Fixed	0	0.46
MEHP	10		0.00270 (-0.00733 to 0.01273)	Fixed	27.4	0.191
MEOHP	9	-	-0.00395 (-0.00995 to 0.00204)	Fixed	0	0.677
Inhibin B			· · · · ·			
MEHHP	5	+	-0.00003 (-0.00196 to 0.00190)	Fixed	0	0.965
MEHP	5		0.00504 (-0.00470 to 0.01478)	Fixed	0	0.888
MEOHP	5	÷	0.00122 (-0.00297 to 0.0054)	Fixed	0	0.746
FT						
MEHHP	6	-	-0.00552 (-0.01115 to 0.00011)	Fixed	34.3	0.179
MEHP	8	⊧_∎_∳	-0.02095 (-0.04742 to 0.00552)	Random	68.1	0.003
MEOHP	6		-0.00656 (-0.01632 to 0.00320)	Fixed	41.6	0.128
FSH						
MEHHP	10	* •	-0.00518 (-0.01007 to -0.00029)	Fixed	34.6	0.131
MEHP	12		0.00276 (-0.00699 to 0.01451)	Fixed	0	0.546
MEOHP	9	* 🔸	-0.00733 (-0.01410 to -0.00056)	Fixed	0	0.616
FAI						
MEHHP	5	*	-0.07799 (-0.12216 to -0.03382)	Fixed	0	0.642
MEHP		*	-0.22769 (-0.33557 to -0.11981)	Fixed	0	0.756
MEOHP	5	*	-0.14837 (-0.22017 to -0.07656)	Fixed	0	0.614
E2						
MEHHP	12	+	0.00190 (-0.00473 to 0.00853)	Random	75.4	<0.001
MEHP	15	┝──■┝┙	-0.01121 (-0.04436 to 0.02194)	Random	85.2	<0.001
MEOHP	12	H <b>H</b> H	0.00138 (-0.01137 to 0.01414)	Random	75.9	<0.001
PROL						
MEHHP	3	┝───╋─┼──┥	-0.03181 (-0.10794 to 0.04432)	Random	58.8	0.088
MEHP	3	⊢∎-1	-0.00272 (-0.02665 to 0.02121)	Fixed	0	0.405
MEOHP	3	<b>⊢−−−−</b>	-0.04759 (-0.16577 to 0.07059)	Random	86.6	0.001
PROG						
MEHP	3	< <b>⊧</b>	→ 0.00328 (-0.47656 to 0.48312)	Random	75.3	0.018
		i i				
		-0.2 0	0.2			

**Figure 2.** Forest plot of urinary DEHP metabolites associated with reproductive hormones in men. MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono-(2-ethyl)-hexyl phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate; TT, total testosterone; SHBG, sex hormone binding-globulin; LH, luteinizing hormone; FT, free testosterone; FSH, follicle-stimulating hormone; FAI, free androgen index; E<sub>2</sub>, estradiol; DHEA-S, dehydroepiandrosterone; PROG, progesterone; PC, percentage change; *p*-value, Cochran's Q test for heterogeneity.

transport and metabolism or genes encoding steroidogenic enzymes.<sup>82</sup> In addition, DEHP is a peroxisome proliferator that can produce a lot of reactive oxygen species (ROS) in vivo.<sup>83</sup> Prenatal exposure to DEHP leads to a decrease in antioxidant capacity by reducing riboflavin<sup>84</sup> and biotin<sup>85</sup> metabolism. Excessive ROS production and inadequate antioxidant defense mechanisms can lead to the development of oxidative stress, which in turn affects HPG and disrupts hormone secretion.<sup>86</sup> Finally, experimental studies revealed pathways by which DEHP reduces testosterone synthesis, including by inhibiting aromatase transcription and activating peroxisome proliferation-activated receptors (PPARs) in granulosa cells<sup>87</sup> and inhibiting the differentiation of Leydig cells during regeneration.<sup>88</sup>

TT, FT, and FAI are common clinical indexes of androgen. Androgens were much higher in men than in postmenopausal women. In the body, most of the circulating testosterone is bound to a protein (SHBG or albumin), while the remaining testosterone (about 2%) is free or unbound, called FT. FAI, calculated as the ratio of TT to SHBG, reflects the status of biologically active androgens.<sup>89</sup> We also found a significant negative correlation between DEHP and FAI, which indicates that DEHP not only lowers the TT concentration but also dramatically inhibits the bioactivity of testosterone in men.

SHBG was negatively associated with MEHHP in postmenopausal women and positively associated with MEOHP in men. SHBG is a serum glycoprotein regulated by the reproductive hormone levels in the body. The opposite effects of SHBG by estrogens and androgens, whereby androgens decrease while estrogens raise SHBG concentration,<sup>18,90</sup> may be responsible for this phenomenon.

The primary female reproductive hormone is  $E_{2\nu}$  which also controls the menstrual cycle and is essential for the growth and upkeep of female reproductive tissues.<sup>91</sup> Exposure to DEHP has been documented to cause both increases and decreases in  $E_2$  levels in humans and animals. Our meta-analysis revealed significant changes in  $E_2$  associated with the DEHP metabolite concentration among postmenopausal women. As an endopubs.acs.org/EnvHealth

TT MEHHP MEHP	9							
	9							
MEHP			•		-0.00277 (-0.00786 to 0.00233)	Fixed	29.5	0.183
	10				-0.00437 (-0.01329 to 0.00455)	Fixed	26.9	0.196
MEOHP	9		4		-0.00661 (-0.01385 to 0.00064)	Fixed	21.3	0.254
SHBG								
MEHHP	7		. H∎∳		-0.01963 (-0.04310 to 0.00384)	Fixed	7.1	0.374
MEHP	6		<b>⊢</b> ∎		0.03189 (-0.01989 to 0.08367)	Fixed	0	0.983
MEOHP	7				-0.00740 (-0.03507 to 0.02028)	Fixed	9.1	0.359
E2								
MEHHP	8		1001		-0.00142 (-0.01407 to 0.01123)	Random	60.5	0.013
MEHP	9		_ <b>⊢</b> ‡→		0.00035 (-0.03661 to 0.03731)	Random	68.9	0.001
MEOHP	8		HEH		-0.00495 (-0.02443 to 0.01453)	Random	67.1	0.003
PROG								
MEHP	4	H		<b></b>	0.16782 (-0.14319 to 0.47884)	Random	84.6	0
FT								
MEHP	4		Hel		-0.01025 (-0.03090 to 0.01041)	Random	65.9	0.032
	<b>-</b> 0	2	0	0.3				

**Figure 3.** Forest plot of urinary DEHP metabolites associated with reproductive hormones in women. MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono-(2-ethyl)-hexyl phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate; TT, total testosterone; SHBG, sex hormone binding-globulin; E<sub>2</sub>, estradiol; FT, free testosterone; PROG, progesterone; PC, percentage change; *p*-value, Cochran's Q test for heterogeneity.

DEHP	age		No. of articles	PC (95%CI)	Model	l² (%)	p-value
тт							
MEHHP	<20	+	4	-0.00219 (-0.00773 to 0.00335)	Fixed	0	0.41
MEHHP	20-45	F	3	-0.00743 (-0.04972 to 0.03486)	Fixed	0	0.872
MEHHP	>45	* 🝝	4	-0.04539 (-0.07296 to -0.01782)	Fixed	48.6	0.12
MEHP	<20	+	5	-0.00019 (-0.01274 to 0.01237)	Fixed	0	0.453
MEHP	20-45	<b>⊢</b>	3	-0.00381 (-0.05089 to 0.04326)	Fixed	0	0.616
MEHP	>45	* 🝝	4	-0.04024 (-0.06563 to -0.01486)	Fixed	39.6	0.174
MEOHP	<20		4	-0.00447 (-0.01311 to 0.00417)	Fixed	24.9	0.262
MEOHP	20-45	<b>⊢</b> ∎-1	3	-0.01389 (-0.05828 to 0.03051)	Fixed	0	0.846
MEOHP	>45	* 🝝	4	-0.04828 (-0.07605 to -0.02050)	Fixed	36.9	0.205
SHBG							
MEHHP	<20	⊢┼╼──┥	3	0.05224 (-0.07967 to 0.18414)	Fixed	0	0.712
MEHHP	20-45	←───₽	2	-0.11925 (-0.44282 to 0.20431)	Fixed	36.9	0.208
MEHHP	>45	Hart I	3	-0.01312 (-0.04182 to 0.01557)	Fixed	0	0.39
MEHP	<20	<	→ 2	0.47220 (-0.81363 to 1.75803)	Fixed	0	0.751
MEHP	20-45	<b>⊢</b>	2	-0.02712 (-0.21808 to 0.16383)	Fixed	0	0.988
MEHP	>45	<b>⊬</b> ∎⊸(	3	0.03530 (-0.01694 to 0.08755)	Fixed	0	0.428
MEOHP	<20		→ 3	0.16850 (-0.09896 to 0.43596)	Fixed	0	0.493
MEOHP	20-45	<b>⊢</b> ∎∔1	2	-0.02923 (-0.08909 to 0.03064)	Fixed	0	0.363
MEOHP	>45	F#4	3	-0.00381 (-0.03524 to 0.02761)	Fixed	7.3	0.34
E2							
MEHHP	<20	<b>⊢</b>	4	-0.02071 (-0.22153 to 0.18010)	Random	55.1	0.083
MEHHP	20-45	•	1	-0.00174 (-0.00579 to 0.00230)	-	-	-
MEHHP	>45	<b>⊢</b> ∎_1	3	-0.06105 (-0.13526 to 0.01317)	Random	51.7	0.126
MEHP	<20	★ *	5	0.03810 (0.01593 to 0.06027)	Fixed	37.4	0.172
MEHP	20-45		1	0.00217 (-0.02051 to 0.02485)	-	-	-
MEHP	>45	┝──━┼─┥	3	-0.04859 (-0.18174 to 0.08457)	Random	74.5	0.02
MEOHP	<20	<	<b>–</b> 4	-0.11451 (-0.61235 to 0.38334)	Random	64.8	0.036
MEOHP	20-45	+	1	-0.00387 (-0.01063 to 0.00289)	-	-	-
MEOHP	>45	* 🕳	3	-0.05349 (-0.08825 to -0.01873)	Fixed	19.2	0.29

**Figure 4.** Forest plot of urinary DEHP metabolites associated with reproductive hormones in women of different age groups. MEHHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono-(2-ethyl)-hexyl phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate; TT, total testosterone; SHBG, sex hormone binding-globulin; PC, percentage change; *p*-value, Cochran's Q test for heterogeneity.

crine-disrupting chemical (EDCs), DEHP mimics naturally occurring estrogen, thereby competing with endogenous estrogen and binding to the ER to ultimately interfere with

or prevent the metabolism of the hormone or receptor in the liver.<sup>92</sup> Furthermore, Takeuchi et al. indicated that DEHP exhibited not only estrogen receptor (ER)  $\alpha$ -mediated

DEHP	No. of articles	1	PC (95%CI) Model / <sup>2</sup> (%)	p-value
TT				
MEHHP	6	<b>⊢_</b> ∎i	0.00809 (-0.03152 to 0.04770) Random 70.6	0.004
MEHP	7	┝──━┼─┥	-0.01241 (-0.05757 to 0.03275) Random 68.6	0.004
MEOHP	5	<b>⊢</b> ,	-0.00074 (-0.02616 to 0.02468) Random 53.1	0.074
SHBG				
MEHHP	4	<b>⊢</b>	-0.00081 (-0.05729 to 0.05567) Fixed 18.8	0.296
MEHP	4	· · · · · · · · · · · · · · · · · · ·	-0.06010 (-0.18805 to 0.06786) Fixed 26.2	0.254
MEOHP	4	· · · · ·	0.04259 (-0.07032 to 0.15551) Fixed 35.6	0.198
LH				
MEHHP	6		0.00231 (-0.00875 to 0.01337) Fixed 36.7	0.162
MEHP	6	⊧∔æ⊸i	0.01044 (-0.01091 to 0.03179) Fixed 41.9	0.126
MEOHP	5		-0.00022 (-0.01019 to 0.00975) Fixed 20.2	0.286
FT				
MEHHP	4	* •	-0.00497 (-0.00980 to -0.00014) Fixed 0	0.496
MEHP	4	⊢−∎−→	-0.04565 (-0.09257 to 0.00128) Random 57.9	0.068
MEOHP	4	* 🔺	-0.00750 (-0.01489 to -0.00011) Fixed 0	0.412
FSH				
MEHHP	6	i ani	-0.01127 (-0.02501 to 0.00246) Fixed 44.5	0.109
MEHP	7		0.00186 (-0.01726 to 0.02097) Fixed 23.8	0.247
MEOHP	5	* 💊	-0.00801 (-0.01551 to -0.00050) Fixed 0	0.532
FAI				
MEHHP	4	* 📥	-0.02783 (-0.05509 to -0.00056) Fixed 0	0.808
MEHP	-4	*	-0.16234 (-0.32093 to -0.00375) Fixed 32.7	0.216
MEOHP	4	*	-0.04718 (-0.08824 to -0.00612) Fixed 0	0.466
E2				
MEHHP	5	┝──╋┼┥	-0.02201 (-0.05768 to 0.01365) Fixed 0	0.594
MEHP	6	· · · · · · · · · · · · · · · · · · ·	-0.05718 (-0.16041 to 0.04604) Random 54.5	0.051
MEOHP	5	▶ <b>■</b>	-0.03818 (-0.09351 to 0.01715) Fixed 0	0.434
		-0.2 0	0.2	

**Figure 5.** Forest plot of urinary DEHP metabolites associated with reproductive hormones in infertile men. MEHHP, mono-(2-ethyl-5hydroxyhexyl) phthalate; MEHP, mono-(2-ethyl)-hexyl phthalate; MEOHP, mono-(2-ethyl-5-oxohexyl) phthalate; TT, total testosterone; SHBG, sex hormone binding-globulin; LH, luteinizing hormone; FT, free testosterone; FSH, follicle-stimulating hormone; FAI, free androgen index;  $E_{2}$ , estradiol; PC, percentage change; *p*-value, Cochran's Q test for heterogeneity.

estrogenic activity but also ER  $\beta$ -mediated antiestrogenic activity in a dose-dependent manner.<sup>78</sup> Hence, DEHP may cause hormonal disorders through the ER.

Subfertility is the failure to conceive after one year of unprotected intercourse.<sup>93</sup> It is reported that subfertility affects 15% of couples worldwide, involving 48.5 million couples.<sup>93</sup> Men were fully responsible for 20-30% of subfertility cases.<sup>94</sup> In our meta-analysis, subjects of the subfertility subgroup are mainly recruited among partners of infertile couples seeking treatment in clinics. The results show that among men of reproductive age, exposure to DEHP was associated with more significant hormonal suppression in infertile men compared with that in fertile men. A previous review summarized the relationship between phthalate (PAE) exposure and male reproductive outcomes, ultimately finding moderate evidence of increased DEHP metabolites related to shorter anogenital distance and lower semen quality.95 Studies revealed that the adverse effects of DEHP exposure on sperm concentration may be partially mediated by reproductive hormones, thereby further contributing to fertility problems in reproductive-age men.<sup>14,47,52</sup> Hence, we cannot determine whether infertile men are more sensitive or whether infertility is also a health effect of DEHP exposure. Finally, we found evidence of negative associations between MEOHP and FSH. FSH usually reflects the feedback between the testes and the hypothalamus/ pituitary gland on the status of spermatogenesis, and its elevation indicates abnormal spermatogenesis.<sup>9</sup>

Age subgroup analysis revealed that postmenopausal women (>45 years old) were more sensitive to DEHP by showing a significant decrease in TT and  $E_2$  concentrations. Although several studies have revealed this phenomenon, it still has not

been addressed why and how postmenopausal women become particularly susceptible to plasticizers.<sup>54,67</sup> It seems not to be the result of exposure levels. Long et al. found that postmenopausal women had lower DEHP exposure than premenopausal women.<sup>67</sup> However, the study by Ding et al. showed no appreciable variations in the concentrations of DEHP metabolites across menopausal stages.<sup>54</sup> Alternatively, postmenopausal women have lower TT with reproductive aging and declining ovarian functions compared with premenopausal women. The reproductive hormones of postmenopausal women tend to stabilize independently of the menstrual cycle,<sup>97</sup> which may explain their greater sensitivity to DEHP. There were no significant differential results for age subgroup analysis in males, partly because of the existing studies focused on men of reproductive age.

Several studies have found that PAE was associated with multiple adverse health outcomes by affecting reproductive hormone levels. Two studies conducted in China showed that LH and androstenedione mediated the association between serum PAE concentration sperm concentration and sperm motility.<sup>59,98</sup> Studies in older men indicated that exposure to DEHP promoted benign prostatic hyperplasia by increasing the level of dihydrotestosterone, E2, and ROS production. Adibi et al. confirmed HCG partially mediates PAE concerning anogenital distance in males and females.<sup>69</sup> In addition, PAE exposure during pregnancy increases the risk of developing postpartum depression by decreasing maternal progesterone concentrations.<sup>99</sup> Finally, some studies link exposure to phthalate metabolites to female obesity,<sup>15</sup> metabolic syndrome, the timing of menarche,<sup>49</sup> premature ovarian failure,<sup>16</sup> delayed pubarche,<sup>100</sup> and self-reported sleep disruptions.<sup>101</sup>

The usage of DEHP is expanding as economies grow, which harms ecosystems and public health.<sup>102</sup> Our study demonstrates the hormone-disrupting effects of DEHP, especially in infertile men and postmenopausal women. Therefore, attention should be paid to taking measures to minimize the adverse effects of DEHP. First, governments can innovate technologies to reduce the emission rate of DEHP by adopting non/low-toxicity alternatives to plasticizers or by replacing polymers without plasticizers.<sup>103,104</sup> The use of phthalates in food and mother and child products should be restricted or suspended,<sup>105</sup> and it is necessary to develop new technologies to improve the degradation rate of DEHP to reduce the burden of DEHP deposition in the environment.<sup>106</sup> Besides, individuals, especially vulnerable populations, can also effectively reduce the burden of DEHP in the body by reducing dietary intake and changing personal habits and behaviors,  $^{105}$ ,  $^{107}$  such as by (1) reducing drinking from plastic cups; (2) reducing the use of plastic packaging for food, especially meat and fat-rich food; (3) avoiding repeated use of disposable plastic packaging; (4) limiting microwaving food in cartons, plastic boxes, or plastic packaging; and (5) stopping use of cosmetics or by using less-scented personal care products.

### 4.1. Strengths and Limitations of This Study

In conclusion, this systematic review and meta-analysis provide the most updated and comprehensive analysis to date of the relationship between urinary DEHP metabolites and serum reproductive hormones, thereby contributing to clarifying the mechanisms of DEHP effects on human health. Nevertheless, several limitations must be considered in this study. First, only minor studies used the sum of DEHP metabolites ( $\Sigma$ DEHP) involving different types of DEHP metabolites. Therefore, the relationship between  $\Sigma$ DEHP and reproductive hormones is still inconclusive. Additionally, only a few studies of male children, adolescents, and older adults limits our further assessment of differences in male age subgroups.

# 4.2. Future Directions

Several potential future extensions of this work are proposed in this paper. First, the half-life of DEHP is very short (<24 h). DEHP is rapidly metabolized after absorption and does not bioaccumulate in the body. However, most of the existing studies used a single urine spot to represent DEHP exposure and ignored the changes in exposure over time. Therefore, more studies with higher sensitivity (i.e., taking into account different exposure time windows with repeated exposure measurements) would be informative. In addition, studies in women should take full account of factors affecting the circulating levels of reproductive hormones, such as menstrual cycle, menstrual status, etc. Moreover, research is urgently needed to determine whether hormone effects from DEHP exposure result in later adverse health outcomes.

# 5. CONCLUSIONS

This systematic review and meta-analysis provide evidence that DEHP metabolites are associated with altered reproductive hormones, including TT, FAI, FSH, and SHBG. DEHP mainly exerts antiandrogenic effects on the human body. Postmenopausal women are more vulnerable to the association of DEHP with lower TT and  $E_2$ . Furthermore, the significant changes in hormones are found in infertile men rather than fertile men, which means DEHP may contribute to other adverse reproductive health outcomes by altering hormone levels. Overall, our findings may provide support for understanding the relationship between DEHP metabolites and reproductive hormones. As the annual production and use of plastics increase dramatically, policymakers should consider the health risks of using DEHP as an additive.

# ASSOCIATED CONTENT

# **Supporting Information**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/envhealth.4c00046.

Additional results from this manuscript in Tables S1–S10 and Figures S1–S20 (PDF)

# AUTHOR INFORMATION

# **Corresponding Authors**

- Shusi Wang Department of Healthcare-associated Infection Management, Hefei Stomatological Hospital, Anhui Medical University Hefei Oral Clinic College, Hefei 230032, China; Email: wangshusi0625@163.com
- Hong Su Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China; orcid.org/0000-0002-4673-6449; Email: suhong5151@sina.com

# Authors

- Xuanxuan Li Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Changchun Xiao Hefei Center for Disease Control and Prevention, Hefei, Anhui 230032, China
- Jintao Liu Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Ning Wei Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Jian Song Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Jiajun Yuan Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Li Liu Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei,

Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China

- Rong Song Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Weizhuo Yi Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Rubing Pan Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China
- Jian Cheng Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, Anhui 230032, China; Center for Big Data and Population Health of IHM, Hefei, Anhui 230032, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui 230032, China

Complete contact information is available at: https://pubs.acs.org/10.1021/envhealth.4c00046

#### **Author Contributions**

<sup>#</sup>X.L. and C.X. contributed equally to this study. X.L., S.W., and L.H.: Conceptualization, Methodology, Data curation, Formal analysis, Writing - original draft, and Writing - review and editing. J.L., N.W., and J.S.: Data curation, Formal analysis, Visualization, and Writing - review and editing. J.Y., L.L., and R.S.: Formal analysis, Methodology, Data curation, and Writing - review and editing. W.Y. and R.P.: Formal analysis, and Methodology. H.S. and C.X.: Supervision, Conceptualization, Validation, Writing - original draft, and Writing review and editing.

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

This work was supported by the National Natural Science Foundation of China (Grant No. 42375184 and 42105165), Research Funds of Center for Big Data and Population Health of IHM (Grant No. JKS2022011), and Natural Science Research Key Project of University of Anhui Province (Grant No. 2023AH050652).

#### REFERENCES

(1) Guo, Y.; Kannan, K. Comparative assessment of human exposure to phthalate esters from house dust in China and the United States. *Environ. Sci. Technol.* **2011**, *45* (8), 3788–94.

(2) Wen, Z. J.; Wang, Z. Y.; Zhang, Y. F. Adverse cardiovascular effects and potential molecular mechanisms of DEHP and its metabolites-A review. *Science of the total environment* **2022**, *847*, 157443.

(3) Center for Devices and Radiological Health. Safety assessment of di(2-ethylhexyl)phthalate (dehp) released from pvc medical devices; U.S. Food and Drug Administration: Rockville, MD. 2001, https://noharm-uscanada.org/sites/default/files/documents-files/116/Safety\_Assessment\_of\_DEHP.pdf.

(4) Erythropel, H. C.; Maric, M.; Nicell, J. A.; Leask, R. L.; Yargeau, V. Leaching of the plasticizer di(2-ethylhexyl)phthalate (DEHP) from plastic containers and the question of human exposure. *Applied microbiology and biotechnology* **2014**, *98* (24), *9967–81*.

(5) Zhang, Y.; Huang, B.; Sabel, C. E.; Thomsen, M.; Gao, X.; Zhong, M.; Chen, Z.; Feng, P. Oral intake exposure to phthalates in vegetables produced in plastic greenhouses and its health burden in Shaanxi province, China. *Science of the total environment* **2019**, *696*, 133921.

(6) Fisher, M.; Arbuckle, T. E.; MacPherson, S.; Braun, J. M.; Feeley, M.; Gaudreau, É. Phthalate and BPA Exposure in Women and Newborns through Personal Care Product Use and Food Packaging. *Environ. Sci. Technol.* **2019**, *53* (18), 10813–10826.

(7) Hahladakis, J. N.; Velis, C. A.; Weber, R.; Iacovidou, E.; Purnell, P. An overview of chemical additives present in plastics: Migration, release, fate and environmental impact during their use, disposal and recycling. *Journal of hazardous materials* **2018**, *344*, 179–199.

(8) Chang, W. H.; Herianto, S.; Lee, C. C.; Hung, H.; Chen, H. L. The effects of phthalate ester exposure on human health: A review. *Science of the total environment* **2021**, *786*, 147371.

(9) Mariana, M.; Castelo-Branco, M.; Soares, A. M.; Cairrao, E. Phthalates' exposure leads to an increasing concern on cardiovascular health. *Journal of hazardous materials* **2023**, 457, 131680.

(10) Mariana, M.; Feiteiro, J.; Verde, I.; Cairrao, E. The effects of phthalates in the cardiovascular and reproductive systems: A review. *Environ. Int.* **2016**, *94*, 758–776.

(11) Yilmaz, B.; Terekeci, H.; Sandal, S.; Kelestimur, F. Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. *Reviews in endocrine & metabolic disorders* **2020**, *21* (1), 127–147.

(12) You, H. H.; Song, G. Review of endocrine disruptors on male and female reproductive systems. *Comparative biochemistry and physiology. Toxicology & pharmacology: CBP* **2021**, 244, 109002.

(13) Mendiola, J.; Meeker, J. D.; Jørgensen, N.; Andersson, A. M.; Liu, F.; Calafat, A. M.; Redmon, J. B.; Drobnis, E. Z.; Sparks, A. E.; Wang, C.; Hauser, R.; Swan, S. H. Urinary concentrations of di(2ethylhexyl) phthalate metabolites and serum reproductive hormones: pooled analysis of fertile and infertile men. *Journal of andrology* **2012**, 33 (3), 488–98.

(14) Chang, W. H.; Li, S. S.; Wu, M. H.; Pan, H. A.; Lee, C. C. Phthalates might interfere with testicular function by reducing testosterone and insulin-like factor 3 levels. *Human reproduction* (*Oxford, England*) **2015**, 30 (11), 2658–70.

(15) Dubey, P.; Reddy, S. Y.; Singh, V.; Shi, T.; Coltharp, M.; Clegg, D.; Dwivedi, A. K. Association of Exposure to Phthalate Metabolites With Sex Hormones, Obesity, and Metabolic Syndrome in US Women. *JAMA network open* **2022**, *5* (9), No. e2233088.

(16) Cao, M.; Pan, W.; Shen, X.; Li, C.; Zhou, J.; Liu, J. Urinary levels of phthalate metabolites in women associated with risk of premature ovarian failure and reproductive hormones. *Chemosphere* **2020**, *242*, 125206.

(17) Su, P. H.; Chen, J. Y.; Lin, C. Y.; Chen, H. Y.; Liao, P. C.; Ying, T. H.; Wang, S. L. Sex steroid hormone levels and reproductive development of eight-year-old children following in utero and environmental exposure to phthalates. *PloS one* **2014**, *9* (9), No. e102788.

(18) Wen, H. J.; Chen, C. C.; Wu, M. T.; Chen, M. L.; Sun, C. W.; Wu, W. C.; Huang, I. W.; Huang, P. C.; Yu, T. Y.; Hsiung, C. A.; Wang, S. L. Phthalate exposure and reproductive hormones and sexhormone binding globulin before puberty - Phthalate contaminatedfoodstuff episode in Taiwan. *PloS one* **2017**, *12* (4), No. e0175536. (19) Pan, Y.; Jing, J.; Dong, F.; Yao, Q.; Zhang, W.; Zhang, H.; Yao, B.; Dai, J. Association between phthalate metabolites and biomarkers of reproductive function in 1066 Chinese men of reproductive age. *Journal of hazardous materials* **2015**, 300, 729–736.

(20) Wang, Y. X.; Zeng, Q.; Sun, Y.; You, L.; Wang, P.; Li, M.; Yang, P.; Li, J.; Huang, Z.; Wang, C.; Li, S.; Dan, Y.; Li, Y. F.; Lu, W. Q. Phthalate exposure in association with serum hormone levels, sperm DNA damage and spermatozoa apoptosis: A cross-sectional study in China. *Environmental research* **2016**, *150*, 557–565.

(21) Chen, Q.; Yang, H.; Zhou, N.; Sun, L.; Bao, H.; Tan, L.; Chen, H.; Ling, X.; Zhang, G.; Huang, L.; Li, L.; Ma, M.; Yang, H.; Wang, X.; Zou, P.; Peng, K.; Liu, T.; Shi, X.; Feng, D.; Zhou, Z.; Ao, L.; Cui, Z.; Cao, J. Phthalate exposure, even below US EPA reference doses, was associated with semen quality and reproductive hormones: Prospective MARHCS study in general population. *Environ. Int.* **2017**, *104*, 58–68.

(22) Chang, W. H.; Tsai, Y. S.; Wang, J. Y.; Chen, H. L.; Yang, W. H.; Lee, C. C. Sex hormones and oxidative stress mediated phthalateinduced effects in prostatic enlargement. *Environ. Int.* **2019**, *126*, 184–192.

(23) Sathyanarayana, S.; Butts, S.; Wang, C.; Barrett, E.; Nguyen, R.; Schwartz, S. M.; Haaland, W.; Swan, S. H. Early Prenatal Phthalate Exposure, Sex Steroid Hormones, and Birth Outcomes. *Journal of clinical endocrinology and metabolism* **2017**, *102* (6), 1870–1878.

(24) Liu, N.; Wang, Y.; Yang, Q.; Lv, Y.; Jin, X.; Giesy, J. P.; Johnson, A. C. Probabilistic assessment of risks of diethylhexyl phthalate (DEHP) in surface waters of China on reproduction of fish. *Environmental pollution (Barking, Essex: 1987)* **2016**, *213*, 482–488.

(25) Hammond, G. L.; Wu, T. S.; Simard, M. Evolving utility of sex hormone-binding globulin measurements in clinical medicine. *Current opinion in endocrinology, diabetes, and obesity* **2012**, *19* (3), 183–9.

(26) Svechnikov, K.; Söder, O. Ontogeny of gonadal sex steroids. Best practice & research. Clinical endocrinology & metabolism **2008**, 22 (1), 95–106.

(27) Lauretta, R.; Sansone, M.; Sansone, A.; Romanelli, F.; Appetecchia, M. Gender in Endocrine Diseases: Role of Sex Gonadal Hormones. *Int. J. Endocrinol.* **2018**, *2018*, 4847376.

(28) Kelly, D. S.; Sabharwal, S.; Ramsey, D. J.; Morkin, M. I. The effects of female sex hormones on the human cornea across a woman's life cycle. *BMC Ophthalmol.* **2023**, *23* (1), 358.

(29) Kit, O. I.; Frantsiyants, E. M.; Moiseenko, T.; Vereskunova, M. I.; Adamyan, M. V.; Saforian, N. S.; Gurnak, V. V.; Ilchenko, M. G. Sex hormones as regulators of levels of growth factors in tissues of multiple primary tumors of female reproductive organs. *J. Clin. Oncol.* **2017**, *35*, e23180.

(30) Brettle, H.; Tran, V.; Drummond, G. R.; Franks, A. E.; Petrovski, S.; Vinh, A.; Jelinic, M. Sex hormones, intestinal inflammation, and the gut microbiome: Major influencers of the sexual dimorphisms in obesity. *Frontiers in immunology* **2022**, *13*, 971048.

(31) Lim, G. B. Role of sex hormones in cardiovascular diseases. *Nature reviews. Cardiology* **2021**, *18* (6), 385.

(32) Hildenbrand, S.; Gabrio, T.; Volland, G. Inter-Day Variability of Metabolites of DEHP and DnBP in Human Urine-Comparability of the Results of Longitudinal Studies with a Cross-Sectional Study. *Int. J. Environ. Res. Public Health* **2019**, *16* (6), 1029.

(33) Xu, J.; Wang, L.; Zhang, L.; Zheng, F.; Wang, F.; Leng, J.; Wang, K.; Héroux, P.; Shen, H. M.; Wu, Y.; Xia, D. Mono-2-ethylhexyl phthalate drives progression of PINK1-parkin-mediated mitophagy via increasing mitochondrial ROS to exacerbate cytotox-icity. *Redox biology* **2021**, *38*, 101776.

(34) Tsochatzis, E. D.; Tzimou-Tsitouridou, R.; Gika, H. G. Analytical Methodologies for the Assessment of Phthalate Exposure in Humans. *Critical reviews in analytical chemistry* **2017**, *47* (4), 279–297.

(35) Kato, K.; Silva, M. J.; Reidy, J. A.; Hurtz, D., 3rd; Malek, N. A.; Needham, L. L.; Nakazawa, H.; Barr, D. B.; Calafat, A. M. Mono(2ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2ethylhexyl) phthalate. *Environ. Health Perspect.* **2004**, *112* (3), 327– 30. (36) Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. *Open Med.* **2009**, *3* (3), No. e123-30. Epub 2009 Jul 21. PMID: 21603045; PMCID: PMC3090117.

(37) Rodríguez-Barranco, M.; Tobías, A.; Redondo, D.; Molina-Portillo, E.; Sánchez, M. J. Standardizing effect size from linear regression models with log-transformed variables for meta-analysis. *BMC Med. Res. Methodol.* **2017**, *17* (1), 44.

(38) Altman, D. G.; Bland, J. M. How to obtain the P value from a confidence interval. *BMJ. (Clinical research ed.)* **2011**, 343, d2304.

(39) Cai, H.; Zheng, W.; Zheng, P.; Wang, S.; Tan, H.; He, G.; Qu, W. Human urinary/seminal phthalates or their metabolite levels and semen quality: A meta-analysis. *Environmental research* **2015**, *142*, 486–94.

(40) Wu, K.; Ho, H. C.; Su, H.; Huang, C.; Zheng, H.; Zhang, W.; Tao, J.; Hossain, M. Z.; Zhang, Y.; Hu, K.; Yang, M.; Wu, Q.; Xu, Z.; Cheng, J. A systematic review and meta-analysis of intraday effects of ambient air pollution and temperature on cardiorespiratory morbidities: First few hours of exposure matters to life. *EBioMedicine* **2022**, *86*, 104327.

(41) Song, R.; Liu, L.; Wei, N.; Li, X.; Liu, J.; Yuan, J.; Yan, S.; Sun, X.; Mei, L.; Liang, Y.; Li, Y.; Jin, X.; Wu, Y.; Pan, R.; Yi, W.; Song, J.; He, Y.; Tang, C.; Liu, X.; Cheng, J.; Su, H. Short-term exposure to air pollution is an emerging but neglected risk factor for schizophrenia: A systematic review and meta-analysis. *Science of the total environment* **2023**, *854*, 158823.

(42) Song, R.; Liu, L.; Wei, N.; Li, X.; Liu, J.; Yuan, J.; Yan, S.; Sun, X.; Mei, L.; Liang, Y.; Li, Y.; Jin, X.; Wu, Y.; Pan, R.; Yi, W.; Song, J.; He, Y.; Tang, C.; Liu, X.; Cheng, J.; Su, H. Short-term exposure to air pollution is an emerging but neglected risk factor for schizophrenia: A systematic review and meta-analysis. *Science of the total environment* **2023**, *854*, 158823.

(43) Inter-Organisation Programme for the Sound Management of Chemicals (IOMC). State of the Science of Endocrine Disrupting Chemicals 2012: Summary for Decision-Makers; Bergman, Å, Heindel, J. J., Jobling, S., Kidd, K. A., Zoeller, R. T., Eds.; World Health Organization, 2013. https://apps.who.int/iris/handle/10665/78102.

(44) Roth, P. L.; Le, H.; Oh, I. S.; Van Iddekinge, C. H.; Bobko, P. Using beta coefficients to impute missing correlations in meta-analysis research: Reasons for caution. *Journal of applied psychology* **2018**, *103* (6), 644–658.

(45) Aimuzi, R.; Wang, Y.; Luo, K.; Jiang, Y. Exposure to phthalates, phenols, and parabens mixture and alterations in sex steroid hormones among adolescents. *Chemosphere* **2022**, *302*, 134834.

(46) Albert, O.; Huang, J. Y.; Aleksa, K.; Hales, B. F.; Goodyer, C. G.; Robaire, B.; Chevrier, J.; Chan, P. Exposure to polybrominated diphenyl ethers and phthalates in healthy men living in the greater Montreal area: A study of hormonal balance and semen quality. *Environ. Int.* **2018**, *116*, 165–175.

(47) Al-Saleh, I.; Coskun, S.; Al-Doush, I.; Al-Rajudi, T.; Abduljabbar, M.; Al-Rouqi, R.; Palawan, H.; Al-Hassan, S. The relationships between urinary phthalate metabolites, reproductive hormones and semen parameters in men attending in vitro fertilization clinic. *Science of the total environment* **2019**, *658*, 982–995.

(48) Axelsson, J.; Rylander, L.; Rignell-Hydbom, A.; Jönsson, B. A.; Lindh, C. H.; Giwercman, A. Phthalate exposure and reproductive parameters in young men from the general Swedish population. *Environ. Int.* **2015**, *85*, 54–60.

(49) Bigambo, F. M.; Zhang, M.; Zhang, J.; Yang, X.; Yu, Q.; Wu, D.; Wang, X.; Xia, Y. Exposure to a mixture of personal care product and plasticizing chemicals in relation to reproductive hormones and menarche timing among 12–19 years old girls in NHANES 2013–2016. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association 2022, 170, 113463.

(50) Bustamante-Montes, L. P.; Borja-Aburto, V. H.; Hernández-Valero, M.; García-Fábila, M. M.; Borja-Bustamante, P.; González-Álvarez, R. Effect of phthalates exposure during perinatal period on hormonal profile in Mexican males during their first months of life. *Toxicology reports* **2021**, *8*, 1399–1403.

(51) Cathey, A. L.; Watkins, D.; Rosario, Z. Y.; Vélez, C.; Alshawabkeh, A. N.; Cordero, J. F.; Meeker, J. D. Associations of Phthalates and Phthalate Replacements With CRH and Other Hormones Among Pregnant Women in Puerto Rico. *Journal of the Endocrine Society* **2019**, *3* (6), 1127–1149.

(52) Chang, W. H.; Wu, M. H.; Pan, H. A.; Guo, P. L.; Lee, C. C. Semen quality and insulin-like factor 3: Associations with urinary and seminal levels of phthalate metabolites in adult males. *Chemosphere* **2017**, *173*, 594–602.

(53) Chen, S. Y.; Hwang, J. S.; Sung, F. C.; Lin, C. Y.; Hsieh, C. J.; Chen, P. C.; Su, T. C. Mono-2-ethylhexyl phthalate associated with insulin resistance and lower testosterone levels in a young population. *Environmental pollution (Barking, Essex: 1987)* **2017**, *225*, 112–117.

(54) Ding, N.; Zheutlin, E.; Harlow, S. D.; Randolph, J. F., Jr; Mukherjee, B.; Park, S. K. Associations Between Repeated Measures of Urinary Phthalate Metabolites With Hormones and Timing of Natural Menopause. J. Endocr. Soc. **2023**, 7 (4), bvad024.

(55) Du, Y. Y.; Guo, N.; Wang, Y. X.; Hua, X.; Deng, T. R.; Teng, X. M.; Yao, Y. C.; Li, Y. F. Urinary phthalate metabolites in relation to serum anti-Müllerian hormone and inhibin B levels among women from a fertility center: a retrospective analysis. *Reproductive Health* **2018**, *15* (1), 33.

(56) Ferguson, K. K.; Peterson, K. E.; Lee, J. M.; Mercado-García, A.; Blank-Goldenberg, C.; Téllez-Rojo, M. M.; Meeker, J. D. Prenatal and peripubertal phthalates and bisphenol A in relation to sex hormones and puberty in boys. *Reproductive toxicology (Elmsford, N.Y.)* **2014**, *47*, 70–6.

(57) Jurewicz, J.; Radwan, M.; Sobala, W.; Ligocka, D.; Radwan, P.; Bochenek, M.; Hawuła, W.; Jakubowski, L.; Hanke, W. Human urinary phthalate metabolites level and main semen parameters, sperm chromatin structure, sperm aneuploidy and reproductive hormones. *Reproductive toxicology (Elmsford, N.Y.)* **2013**, *42*, 232–41.

(58) Meeker, J. D.; Calafat, A. M.; Hauser, R. Urinary metabolites of di(2-ethylhexyl) phthalate are associated with decreased steroid hormone levels in adult men. *Journal of andrology* **2009**, *30* (3), 287–97.

(59) Wang, B.; Qin, X.; Xiao, N.; Yao, Y.; Duan, Y.; Cui, X.; Zhang, S.; Luo, H.; Sun, H. Phthalate exposure and semen quality in infertile male population from Tianjin, China: Associations and potential mediation by reproductive hormones. *Science of the total environment* **2020**, 744, 140673.

(60) Watkins, D. J.; Téllez-Rojo, M. M.; Ferguson, K. K.; Lee, J. M.; Solano-Gonzalez, M.; Blank-Goldenberg, C.; Peterson, K. E.; Meeker, J. D. In utero and peripubertal exposure to phthalates and BPA in relation to female sexual maturation. *Environmental research* **2014**, *134*, 233–41.

(61) Wen, H. J.; Sie, L.; Su, P. H.; Chuang, C. J.; Chen, H. Y.; Sun, C. W.; Huang, L. H.; Hsiung, C. A.; Julie Wang, S. L. Prenatal and childhood exposure to phthalate diesters and sex steroid hormones in 2-, 5-, 8-, and 11-year-old children: A pilot study of the Taiwan Maternal and Infant Cohort Study. *Journal of epidemiology* **2017**, 27 (11), 516–523.

(62) Xie, C.; Zhao, Y.; Gao, L.; Chen, J.; Cai, D.; Zhang, Y. Elevated phthalates' exposure in children with constitutional delay of growth and puberty. *Molecular and cellular endocrinology* **2015**, 407, 67–73.

(63) Zhu, Y. D.; Han, X.; Wang, X. Q.; Ge, T. X.; Liu, H.; Fan, L.; Li, L.; Su, L. Q.; Wang, X. L. Effect of the phthalates exposure on sex steroid hormones in the US population. *Ecotoxicology and environmental safety* **2022**, 231, 113203.

(64) Nobles, C. J.; Mendola, P.; Kim, K.; Pollack, A. Z.; Mumford, S. L.; Perkins, N. J.; Silver, R. M.; Schisterman, E. F. Preconception Phthalate Exposure and Women's Reproductive Health: Pregnancy, Pregnancy Loss, and Underlying Mechanisms. *Environ. Health Perspect.* **2023**, *131* (12), 127013.

(65) Zhang, J.; Yin, W.; Li, P.; Hu, C.; Wang, L.; Li, T.; Gao, E.; Hou, J.; Wang, G.; Wang, X.; Wang, L.; Yu, Z.; Yuan, J. Interaction

764

between diet- and exercise-lifestyle and phthalates exposure on sex hormone levels. *Journal of hazardous materials* **2019**, *369*, 290–298. (66) Liu, J.; Gao, D.; Li, Y.; Song, X.; Chen, M.; Ma, Q.; Wang, X.; Cui, M.; Guo, T.; Chen, L.; Zhang, Y.; Yuan, W.; Ma, T.; Jiang, J.; Dong, Y.; Zou, Z.; Ma, J. Persistent high exposure to exogenous phthalates and endogenous sex hormones associated with early pubertal onset among children: A 3.5-year longitudinal cohort study in China. *Ecotoxicology and environmental safety* **2023**, *262*, 115199.

(67) Long, S. E.; Kahn, L. G.; Trasande, L.; Jacobson, M. H. Urinary phthalate metabolites and alternatives and serum sex steroid hormones among pre- and postmenopausal women from NHANES, 2013–16. Science of the total environment **2021**, 769, 144560.

(68) Henrotin, J. B.; Feigerlova, E.; Robert, A.; Dziurla, M.; Burgart, M.; Lambert-Xolin, A. M.; Jeandel, F.; Weryha, G. Decrease in serum testosterone levels after short-term occupational exposure to diisononyl phthalate in male workers. *Occupational and environmental medicine* **2020**, 77 (4), 214–222.

(69) Adibi, J. J.; Lee, M. K.; Naimi, A. I.; Barrett, E.; Nguyen, R. H.; Sathyanarayana, S.; Zhao, Y.; Thiet, M. P.; Redmon, J. B.; Swan, S. H. Human Chorionic Gonadotropin Partially Mediates Phthalate Association With Male and Female Anogenital Distance. *J. Clin. Endocrinol. Metab.* **2015**, *100* (9), E1216–E1224.

(70) Génard-Walton, M.; McGee, G.; Williams, P. L.; Souter, I.; Ford, J. B.; Chavarro, J. E.; Calafat, A. M.; Hauser, R.; Mínguez-Alarcón, L. Mixtures of urinary concentrations of phenols and phthalate biomarkers in relation to the ovarian reserve among women attending a fertility clinic. *Science of the total environment* **2023**, *898*, 165536.

(71) Myridakis, A.; Balaska, E.; Gkaitatzi, C.; Kouvarakis, A.; Stephanou, E. G. Determination and separation of bisphenol A, phthalate metabolites and structural isomers of parabens in human urine with conventional high-pressure liquid chromatography combined with electrospray ionisation tandem mass spectrometry. *Anal. Bioanal. Chem.* **2015**, 407 (9), 2509–18.

(72) Kato, K.; Silva, M. J.; Needham, L. L.; Calafat, A. M. Determination of 16 phthalate metabolites in urine using automated sample preparation and on-line preconcentration/high-performance liquid chromatography/tandem mass spectrometry. *Analytical chemistry* **2005**, 77 (9), 2985–91.

(73) Zhang, X.; Qiu, T.; Fu, H.; Yang, Y.; Zhao, F.; Lin, S.; Hu, X. [Determination of nine phthalate ester metabolites in human urine using ultra high performance liquid chromatography-tandem triple quadrupole mass spectrometry]. *Se P'u Chin. J. Chromatogr.* **2018**, *36* (9), 895–903.

(74) Yuan, T. F.; Le, J.; Cui, Y.; Peng, R.; Wang, S. T.; Li, Y. An LC-MS/MS analysis for seven sex hormones in serum. *J. Pharm. Biomed. Anal.* **2019**, *162*, 34–40.

(75) Stanczyk, F. Z.; Jurow, J.; Hsing, A. W. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. *Cancer* epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology **2010**, 19 (4), 903–6.

(76) Xu, Z.; Wang, W.; Liu, Q.; Li, Z.; Lei, L.; Ren, L.; Deng, F.; Guo, X.; Wu, S. Association between gaseous air pollutants and biomarkers of systemic inflammation: A systematic review and metaanalysis. *Environmental pollution (Barking, Essex: 1987)* **2022**, 292 (Pt A), 118336.

(77) Derakhshan, A.; Shu, H.; Broeren, M. A. C.; Kortenkamp, A.; Lindh, C. H.; Demeneix, B.; Peeters, R. P.; Bornehag, C. G.; Korevaar, T. I. M. Association of endocrine disrupting chemicals exposure with human chorionic gonadotropin concentrations in pregnancy. *Environ. Int.* **2023**, *178*, 108091.

(78) Takeuchi, S.; Iida, M.; Kobayashi, S.; Jin, K.; Matsuda, T.; Kojima, H. Differential effects of phthalate esters on transcriptional activities via human estrogen receptors alpha and beta, and androgen receptor. *Toxicology* **2005**, *210* (2–3), 223–33.

(79) Shifren, J. L.; Davis, S. R. Androgens in postmenopausal women: a review. *Menopause (New York, N.Y.)* 2017, 24 (8), 970–979.

(80) Zhai, L. L.; Zhao, J.; Bai, Y. L.; Wei, W.; Sun, Q.; Jia, L. H. Combined effects of obesity and di-(2-ethylhexyl) phthalate on testosterone levels and kisspeptin/GPR54 expression in hypothalamus and testes of male mice. *Journal of the Chinese Medical Association: JCMA* **2020**, *83* (11), 1020–1028.

(81) Capela, D.; Poissenot, K.; Dombret, C.; Keller, M.; Franceschini, I.; Mhaouty-Kodja, S. Effects of combined exposure of adult male mice to di-(2-ethylexyl)phthalate and nonylphenol on behavioral and neuroendocrine responses. *Chemosphere* **2019**, *221*, 573–582.

(82) Desdoits-Lethimonier, C.; Albert, O.; Le Bizec, B.; Perdu, E.; Zalko, D.; Courant, F.; Lesné, L.; Guillé, F.; Dejucq-Rainsford, N.; Jégou, B. Human testis steroidogenesis is inhibited by phthalates. *Human reproduction (Oxford, England)* **2012**, *27* (5), 1451–9.

(83) Erkekoğlu, P.; Rachidi, W.; Yüzügüllü, O. G.; Giray, B.; Oztürk, M.; Favier, A.; Hıncal, F. Induction of ROS, p53, p21 in DEHP- and MEHP-exposed LNCaP cells-protection by selenium compounds. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association **2011**, 49 (7), 1565–71.

(84) Tang, J.; Hu, J.; Xue, M.; Guo, Z.; Xie, M.; Zhang, B.; Zhou, Z.; Huang, W.; Hou, S. Maternal diet deficient in riboflavin induces embryonic death associated with alterations in the hepatic proteome of duck embryos. *Nutrition & metabolism* **2019**, *16*, 19.

(85) Madsen, C. T.; Sylvestersen, K. B.; Young, C.; Larsen, S. C.; Poulsen, J. W.; Andersen, M. A.; Palmqvist, E. A.; Hey-Mogensen, M.; Jensen, P. B.; Treebak, J. T.; Lisby, M.; Nielsen, M. L. Biotin starvation causes mitochondrial protein hyperacetylation and partial rescue by the SIRT3-like deacetylase Hst4p. *Nat. Commun.* **2015**, *6*, 7726.

(86) Darbandi, M.; Darbandi, S.; Agarwal, A.; Sengupta, P.; Durairajanayagam, D.; Henkel, R.; Sadeghi, M. R. Reactive oxygen species and male reproductive hormones. *Reprod. Biol. Endocrinol.* **2018**, *16* (1), 87.

(87) Hannon, P. R.; Flaws, J. A. The effects of phthalates on the ovary. *Front. Endocrinol.* **2015**, *6*, 8.

(88) Li, X. W.; Liang, Y.; Su, Y.; Deng, H.; Li, X. H.; Guo, J.; Lian, Q. Q.; Ge, R. S. Adverse effects of di-(2-ethylhexyl) phthalate on Leydig cell regeneration in the adult rat testis. *Toxicology letters* **2012**, 215 (2), 84–91.

(89) Georgiopoulos, G. A.; Lambrinoudaki, I.; Athanasouli, F.; Armeni, E.; Rizos, D.; Kazani, M.; Karamanou, M.; Manios, E.; Augoulea, A.; Stellos, K.; Papamichael, C.; Stamatelopoulos, K. Free androgen index as a predictor of blood pressure progression and accelerated vascular aging in menopause. *Atherosclerosis* **2016**, *247*, 177–83.

(90) Thaler, M. A.; Seifert-Klauss, V.; Luppa, P. B. The biomarker sex hormone-binding globulin - from established applications to emerging trends in clinical medicine. *Best practice & research. Clinical endocrinology & metabolism* **2015**, *29* (5), 749–60.

(91) Lizcano, F.; Guzmán, G. Estrogen Deficiency and the Origin of Obesity during Menopause. *BioMed. research international* **2014**, 2014, 757461.

(92) Katsikantami, I.; Sifakis, S.; Tzatzarakis, M. N.; Vakonaki, E.; Kalantzi, O. I.; Tsatsakis, A. M.; Rizos, A. K. A global assessment of phthalates burden and related links to health effects. *Environ. Int.* **2016**, *97*, 212–236.

(93) Agarwal, A.; Mulgund, A.; Hamada, A.; Chyatte, M. R. A unique view on male infertility around the globe. *Reprod. Biol. Endocrinol.* **2015**, *13*, 37.

(94) Vander Borght, M.; Wyns, C. Fertility and infertility: Definition and epidemiology. *Clinical biochemistry* **2018**, *62*, 2–10.

(95) Radke, E. G.; Braun, J. M.; Meeker, J. D.; Cooper, G. S. Phthalate exposure and male reproductive outcomes: A systematic review of the human epidemiological evidence. *Environment International* **2018**, *121*, 764–793.

(96) Simoni, M.; Gromoll, J.; Nieschlag, E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. *Endocr. Rev.* **1997**, *18* (6), 739–73.

(97) Rothman, M. S.; Carlson, N. E.; Xu, M.; Wang, C.; Swerdloff, R.; Lee, P.; Goh, V. H.; Ridgway, E. C.; Wierman, M. E. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. *Steroids* **2011**, *76* (1–2), 177–82.

(98) Yuan, G.; Zeng, Y.; Hu, G.; Liu, Y.; Wei, L.; Liu, P.; Liu, G.; Cheng, J. Inverse association of certain seminal phthalate metabolites with semen quality may be mediated by androgen synthesis: A cross-sectional study from the South China. *Environ. Int.* **2021**, *151*, 106459.

(99) Jacobson, M. H.; Stein, C. R.; Liu, M.; Ackerman, M. G.; Blakemore, J. K.; Long, S. E.; Pinna, G.; Romay-Tallon, R.; Kannan, K.; Zhu, H.; Trasande, L. Prenatal Exposure to Bisphenols and Phthalates and Postpartum Depression: The Role of Neurosteroid Hormone Disruption. *Journal of clinical endocrinology and metabolism* **2021**, *106* (7), 1887–1899.

(100) Frederiksen, H.; Sørensen, K.; Mouritsen, A.; Aksglaede, L.; Hagen, C. P.; Petersen, J. H.; Skakkebaek, N. E.; Andersson, A. M.; Juul, A. High urinary phthalate concentration associated with delayed pubarche in girls. *International journal of andrology* **2012**, 35 (3), 216–26.

(101) Hatcher, K. M.; Smith, R. L.; Chiang, C.; Li, Z.; Flaws, J. A.; Mahoney, M. M. Association of phthalate exposure and endogenous hormones with self-reported sleep disruptions: results from the Midlife Women's Health Study. *Menopause (New York, N.Y.)* **2020**, 27 (11), 1251–1264.

(102) Chapon, V.; Brignon, J. M.; Gasperi, J. Non-persistent chemicals in polymer and non-polymer products can cause persistent environmental contamination: evidence with DEHP in Europe. *Environmental science and pollution research international* **2023**, 30 (15), 44952–44962.

(103) Cui, Y.; Chen, J.; Wang, Z.; Wang, J.; Allen, D. T. Coupled Dynamic Material Flow, Multimedia Environmental Model, and Ecological Risk Analysis for Chemical Management: A Di(2-ethylhexhyl) Phthalate Case in China. *Environ. Sci. Technol.* **2022**, *56* (15), 11006–11016.

(104) Simmchen, J.; Ventura, R.; Segura, J. Progress in the removal of di-[2-ethylhexyl]-phthalate as plasticizer in blood bags. *Transfusion medicine reviews* **2012**, *26* (1), 27–37.

(105) Chen, C. Y.; Chou, Y. Y.; Lin, S. J.; Lee, C. C. Developing an intervention strategy to reduce phthalate exposure in Taiwanese girls. *Science of the total environment* **2015**, *517*, 125–31.

(106) Zhang, K.; Wu, X.; Luo, H.; Wang, W.; Yang, S.; Chen, J.; Chen, W.; Chen, J.; Mo, Y.; Li, L. Biochemical pathways and enhanced degradation of dioctyl phthalate (DEHP) by sodium alginate immobilization in MBR system. *Water science and technology: a journal of the International Association on Water Pollution Research* **2021**, 83 (3), 664–677.

(107) Rowdhwal, S. S. S.; Chen, J. Toxic Effects of Di-2-ethylhexyl Phthalate: An Overview. *BioMed Res. Int.* **2018**, 2018, 1750368.